Pacylex News

First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a patient published

Pacylex is excited to announce the publication in the journal Current Oncology  of data from the first patient. The paper entitled “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-cell Lymphoma describes how an eighty-six year old woman with relapsed diffuse large B-cell lymphoma (DLBCL) received oral PCLX-001, a small molecule, N-myristoyltransferase (NMT) inhibitor, as the initial patient in a phase 1 dose escalation clinical trial.

Click here for the full story

March 14, 2022